Skip to main content
    U

    Ultragenyx (RARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.43
    -0.14 (-0.90%)

    Market Cap: $1.59B

    Last updated: Nov 06, 2026 at 4:41 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    35%(14/40)
    Avg Surprise
    -12.89%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.87
    Range$-1.75 - $2.03
    6 analysts
    Revenue Consensus
    $238M
    Range$179M - $380M
    19 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.87$-1.75 - $2.03--6--
    Sep 26
    Reported Nov 3
    		$-1.16$-1.15$-1.25 - $0.75-0.87%Miss6
    0
    1
    30d
    		+35.9%
    Jun 26
    Reported Aug 4
    		$-0.90$-1.27$-1.48 - $-1.06+29.13%Beat2
    0
    3
    30d
    		+23.1%
    Mar 26
    Reported May 5
    		$-1.54$-1.46$-2.01 - $-0.78-5.48%Miss11
    0
    2
    30d
    		+1.9%
    Dec 25
    Reported Feb 12
    		$-1.29$-1.17$-1.76 - $-0.71-10.26%Miss12
    2
    1
    30d
    		+7.2%
    Sep 25
    Reported Nov 4
    		$-1.81$-1.21$-1.39 - $-0.98-49.59%Miss12
    3
    2
    30d
    		-29.3%
    Jun 25
    Reported Aug 5
    		$-1.17$-1.32$-1.41 - $-1.11+11.36%Beat11
    7
    1
    30d
    		+23.0%
    Mar 25
    Reported May 6
    		$-1.57$-1.64$-2.41 - $-1.18+4.27%Beat10
    0
    1
    30d
    		+22.7%
    Dec 24
    Reported Feb 13
    		$-1.39$-1.27$-1.48 - $-1.01-9.45%Miss11
    2
    0
    30d
    		+8.6%
    Sep 24
    Reported Nov 5
    		$-1.40$-1.47$-1.76 - $-0.88+4.76%Beat18
    1
    0
    30d
    		+37.2%
    Jun 24
    Reported Aug 1
    		$-1.52$-1.63$-2.13 - $-1.41+6.75%Beat17
    2
    0
    30d
    		+32.4%
    Mar 24
    Reported May 2
    		$-2.03$-1.72$-2.04 - $-1.39-18.02%Miss18
    1
    0
    30d
    		+12.9%
    Dec 23
    Reported Feb 15
    		$-1.52$-1.61$-2.45 - $-0.71+5.59%Beat16
    1
    0
    30d
    		+30.6%

    Key Metrics

    Valuation
    P/E Ratio-3.16EV/EBITDAN/A
    Price/FCF-3.57xFCF Yield-28.04%
    Profitability
    Profit Margin-71.80%Operating Margin-63.60%
    ROE-608.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-5.67x
    Current Ratio1.40xQuick Ratio1.25x
    Trading Statistics
    Beta0.36Avg Volume3.65M
    52-Week High$39.8952-Week Low$12.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.40
    SMA 20$15.87
    SMA 50$16.02
    SMA 200$22.73
    EMA 10$16.12
    EMA 20$16.03
    EMA 50$17.31
    EMA 200$22.69

    MACD

    Line: -0.01Signal: -0.08Hist: 0.07

    ADX

    ADX: 15.8+DI: 25.6-DI: 22.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$17.63

    Bollinger Bands

    Upper Band$17.42
    Lower Band$14.33
    %B Position1946%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    44.6

    Momentum Oscillators

    Stoch %K44.5
    Stoch %D59.0
    Williams %R-83.6
    ROC (10d)-1.4%
    Momentum-0.22
    CCI (20d)-41.6
    MFI (14d)60.5

    Volatility Measures

    ATR (14d)$0.92(6.0%)
    StdDev (20d)0.77
    Hist Vol56.6%(High)

    Volume Flow

    VWAP$15.51
    OBV-12.1M
    AD Line27.5M
    CMF (20d)0.009

    Volume Metrics

    Avg Vol (20d)3.6M
    Vol Ratio1.1x
    VWMA (20d)$15.93

    Pivot Points

    R3$18.26
    R2$17.69
    R1$16.63
    Pivot Point$16.06
    S1$15.00
    S2$14.43
    S3$13.37

    Advanced Oscillators

    TSI-0.12
    Ultimate Osc39.5
    KST106.73

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$173.00M$214.00M$136.00M$207.28M$160.00M$167.00M$139.00M$164.65M$139.49M$147.03M$108.83M$127.14M
    Cost of Revenue$32.00M$34.00M$30.00M$29.34M$28.00M$23.00M$29.00M$17.17M$21.02M$21.28M$17.53M$11.84M
    Gross Profit$141.00M$180.00M$106.00M$177.93M$132.00M$144.00M$110.00M$147.48M$118.47M$125.75M$91.30M$115.30M
    Operating Expenses$251.00M$255.00M$275.00M$291.22M$303.00M$252.00M$253.00M$269.79M$250.46M$242.11M$256.65M$237.14M
    R&D$154.00M$167.00M$187.00M$203.28M$216.00M$165.00M$166.00M$187.90M$170.11M$161.50M$178.49M$160.11M
    SG&A$97.00M$88.00M$88.00M$87.94M$87.00M$87.00M$87.00M$81.89M$80.35M$80.60M$78.16M$77.03M
    Operating Income$-110,000,000$-75,000,000$-169,000,000$-113,283,000$-171,000,000$-108,000,000$-143,000,000$-122,305,000$-131,987,000$-116,361,000$-165,347,000$-121,841,000
    Interest Income$3.00M$5.00M$6.00M$6.00M$6.00M$6.00M$7.00M$9.61M$11.41M$3.41M$12.57M$10.36M
    Interest Expense$20.00M$22.00M$21.00M$19.47M$14.00M$14.00M$14.00M$15.48M$15.71M$15.96M$15.85M$17.32M
    Income Before Tax$-127,000,000$-91,000,000$-184,000,000$-127,686,000$-179,000,000$-114,000,000$-150,000,000$-132,818,000$-133,213,000$-130,740,000$-170,229,000$-127,428,000
    Income Tax Expense$-9,000,000$1.00M$1.00M$870,000$1.00M$1.00M$1.00M$384,000$303,000$858,000$455,000$-3,877,000
    Net Income$-118,000,000$-92,000,000$-185,000,000$-128,556,000$-180,000,000$-115,000,000$-151,000,000$-133,202,000$-133,516,000$-131,598,000$-170,684,000$-123,551,000
    EBITDA$-101,000,000$-66,000,000$-162,000,000$-105,948,000$-164,000,000$-98,000,000$-136,000,000$-120,594,000$-123,268,000$-112,275,000$-161,863,000$-116,355,000
    EBIT$-110,000,000$-74,000,000$-169,000,000$-114,217,000$-171,000,000$-106,000,000$-143,000,000$-126,948,000$-128,910,000$-118,190,000$-166,952,000$-120,461,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RARE

    News

    Ultragenyx Submits Sanfilippo Gene Therapy Marketing Application in UK

    Ultragenyx Pharmaceutical has submitted a marketing application to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its gene therapy, UX111...

    GenomeWeb•11/6/26•Somewhat-Bullish

    Children with Sanfilippo syndrome have limited treatment options. A therapy is under UK review.

    Ultragenyx announced that its investigational gene therapy, UX111 (rebisufligene etisparvovec), for Sanfilippo syndrome Type...

    Stock Titan•11/6/26•Bullish

    Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

    Ultragenyx announced that its Marketing Authorisation Application (MAA) for UX111, an investigational gene therapy for Sanfilippo syndrome Type...

    Quantisnow•11/5/26•Somewhat-Bullish

    Barclays maintains Ultragenyx Pharmaceutical at Overweight, lowers price target to $32 from $35

    Barclays has reiterated its "Overweight" rating for Ultragenyx Pharmaceutical (RARE) but adjusted its price target down from $35 to $32...

    TradingView•11/5/26•Somewhat-Bullish

    TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18

    TD Cowen has reiterated its "Buy" rating for Ultragenyx Pharmaceutical (RARE) and increased its price target to $19 from $18...

    TradingView•11/4/26•Bullish

    RARE Valuation and Fair Value

    P/E
    -3.2x
    P/FCF
    -3.6x
    PEG
    -0.2x
    P/B
    -4.2x
    See GNG's fair value

    RARE Profitability: Margins, ROIC and FCF

    Gross margin
    82.8%
    Operating margin
    -63.6%
    Net margin
    -71.8%
    ROE
    -608.0%
    FCF margin
    -60.5%
    FCF yield
    -28.0%

    RARE Competitors

    CompanyTicker
    Sellas Life Sciences Group IncSLS
    Alignment Healthcare LLCALHC
    Novavax IncNVAX
    CONMED CorporationCNMD
    Nurix Therapeutics IncNRIX
    Ocular Therapeutix IncOCUL
    Butterfly Network IncBFLY
    RAPT Therapeutics IncRAPT

    Sector: Healthcare

    RARE Analyst Ratings

    Consensus
    Buy
    Analysts
    21
    Strong Buy
    2
    Buy
    8
    Hold
    11
    Sell
    0
    Strong Sell
    0

    RARE Bull Case vs Bear Case

    Bear case

    • RARE has a -71.8% net profit margin.
    • RARE beat EPS estimates in 37.5% of its last 8 reported quarters.

    RARE Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -3.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.87

    RARE Earnings Date

    RARE reports Feb 10, 2027, after the close. The date is estimated.

    RARE Earnings Call

    The latest RARE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    RARE ETF Holders

    GNG tracks 10 ETFs that hold RARE. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.85% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.10% of the fund
    3. iShares Biotechnology ETF (IBB), 0.10% of the fund
    4. Vanguard Extended Market Index Fund ETF Shares (VXF), 0.08% of the fund
    5. Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.04% of the fund
    Open the ETF Stock Exposure tool for RARE

    See insider activity

    Frequently Asked Questions About RARE

    When does RARE report earnings?

    Ultragenyx (RARE) is expected to report earnings on Feb 10, 2027.

    Does RARE pay dividends?

    Ultragenyx (RARE) does not currently pay a regular dividend.

    What is RARE's market cap?

    Ultragenyx (RARE) has a market capitalization of $1.59B with a current stock price of $15.43.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In